OVEREXPRESSION OF VIRAL miRs IN HTLV-1, HBV AND HCV INFECTION LEADS TO IMMUNOPATHOGENESIS IN THE DEVELOPMENT OF CANCER
Abstract
MicroRNAs (miRs) are small non-coding molecules, considered excellent clinical biomarkers; however, they are more unstable in circulation than other classes of nucleic acids. The intricate host-virus interaction, by modulating the miR pathway, generally promotes viral persistence by decreasing immune detection. For data analysis, studies were selected from the NCBI, VHL, LILACS, and SciELO databases that discuss the pathogenesis orchestrated by oncogenic miRs in HTLV-1, HBV, and HCV infections. As a complementary strategy, experimental articles were also selected to serve as the basis for presenting the results. A total of 180 articles were found, and the inclusion criteria encompassed experimental studies, controlled trials, and literature reviews. Among these, six experimental articles were selected to comprise the results of this work, as they met the established criteria. This review elucidated the molecular mechanisms associated with HTLV-1, HBV, and HCV infection. The results show that several miRs are associated with leukemic transformation in the ATL group, reinforcing the potential involvement of these molecules in the pathogenesis of HTLV-1–associated ATL. Additionally, the regulation of these molecules is altered in HBV and HCV infections, in which these hepatotropic viruses deregulate pathways such as NF-κB, PI3K/AKT/mTOR, TP53, and WNT through various mechanisms, leading to uncontrolled hepatocarcinogenesis.
Author Biographies
Bachelor’s Degree in Biological Sciences (Teaching Degree). Specialist in Clinical and Diagnostic Analyses. Specialist in Pharmacy and Public Health. Master’s Degree in Genetics and Molecular Biology.
Bachelor’s Degree in Biomedicine. Master’s and PhD in Biology of Infectious and Parasitic Agents.
Physician at the UFPA/EBSERH Hospital Complex. Master’s and PhD in the field of Biology of Infectious and Parasitic Agents from UFPA. Postdoctoral fellow in Higher Education in Health Sciences from UNIFESP.
Bachelor’s Degree in Biomedicine. Specialist in Microbiology. Holds a Professional Master’s Degree in Clinical Analyses.
Bachelor’s Degree in Biological Sciences. Master’s Degree in Parasitic Biology in the Amazon. PhD in Virology.
Bachelor’s Degree in Physiotherapy. Master’s Degree in Biology of Infectious and Parasitic Agents.
Bachelor’s Degree in Biomedicine. Specialist through a Multiprofessional Residency in Integrated Clinical Care.
Bachelor’s Degree in Medicine. Specialist in Microbiology. Master’s Degree in Biology of Infectious and Parasitic Agents.
Bachelor’s Degree in Pharmacy. Master’s and PhD in Biology of Infectious and Parasitic Agents.
References
1. Rojas-Pirela M, Rodriguez-Morales AJ, Rojas M, Bonilla-Aldana DK, Suárez JA, Diaz-Quijano FA, Ortega H. MicroRNAs: master regulators in host-parasitic protist interactions. Open Biol. 2022;6(12):1–25.
2. Dass D, Flores O, Akhrymuk I, Atasheva S, Frolova EI, Frolov I. miRNAs in Herpesvirus Infection: Powerful Regulators in Small Packages. Viruses. 2023;15:1–22.
3. Bondada MS, Reddy PB, Vemula SV, Chvatal S, Lupiani B, Reddy SM. Multifunctional miR-155 Pathway in Avian Oncogenic Virus-Induced Neoplastic Diseases. Noncoding RNA. 2019;5:1–13.
4. MacLennan SA, Marra MA. Oncogenic Viruses and the Epigenome: How Viruses Hijack Epigenetic Mechanisms to Drive Cancer. Int J Mol Sci. 2023;24:1–20.
5. Machado CB, Cavassin FB, Caterino-de-Araujo A, Kashima S, Covas DT, Passos GA. Role of miRNAs in Human T Cell Leukemia Virus Type 1 Induced T Cell Leukemia: A Literature Review and Bioinformatics Approach. Int J Mol Sci. 2022;23:1–18.
6. Souza DRV, Kashima S, Covas DT, Slavov SN. Small RNA profiles of HTLV-1 asymptomatic carriers with monoclonal and polyclonal rearrangement of the T-cell antigen receptor γ-chain using massively parallel sequencing: A pilot study. Oncol Lett. 2020;20:2311–21.
7. D’Agostinho DM, Kashima S, Covas DT, Slavov SN. MiR-150 in HTLV-1 infection and T-cell transformation. Front Immunol. 2022;13:1–9.
8. Bouzar AB, Willems L. How HTLV-1 may subvert miRNAs for persistence and transformation. Retrovirology. 2008;5:1–6.
9. Nascimento A, Andrade RG, Oliveira MF, Brito LM, Cordeiro T, Andrade SP, Kashima S, Covas DT, Slavov SN. Global expression of noncoding RNome reveals dysregulation of small RNAs in patients with HTLV-1–associated adult T-cell leukemia: a pilot study. Infect Agents Cancer. 2021;16:1–13.
10. Xiao C, Calado DP, Galler G, Thai TH, Patterson HC, Wang J, Rajewsky N, Bender TP, Rajewsky K. MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell. 2007;131(1):146–59.
11. Ito M, Teshima K, Ikeda S, Kitabayashi A, Kurosawa S, Amano J, Ishida T, Inagaki H, Ueda R. MicroRNA-150 inhibits tumor invasion and metastasis by targeting the chemokine receptor CCR6 in advanced cutaneous T-cell lymphoma. Blood. 2014;123:1499–511.
12. Bellon M, Lepelletier Y, Hermine O, Nicot C. Deregulation of microRNA involved in hematopoiesis and the immune response in HTLV-I adult T-cell leukemia. Blood. 2009;113:4914–7.
13. Alpuché-Lazcano SP, Jiménez-Hernández LE, López S, Peralta-Zaragoza O, Vázquez-Valls E, Valle-Mendiola A, Madrid-Marina V, Hernández-Montes J, Sánchez-Suárez L, García-Carrancá A. MicroRNAs and long non-coding RNAs during transcriptional regulation and latency of HIV and HTLV. Retrovirology. 2024;21:1–20.
14. Fochi S, Ciminale V, Trindade E, Bidoia C, D’Agostino DM, Silva TC, Pinon JM, De Oliveira Pereira MC, Bittencourt AL, Smole U, Koralnik IJ, De Thé G, Segurado AC, Covas DT, Kashima S, Slavov SN. NF-κB and MicroRNA Deregulation Mediated by HTLV-1 Tax and HBZ. Pathogens. 2019;8:1–18.
15. Rahman S, Hoh J, Thapa R, Pope J, Kim CJ, Afonso PV, Franchini G, Feuer G. HTLV-1 Tax mediated downregulation of miRNAs associated with chromatin remodeling factors in T cells with stably integrated viral promoter. PLoS One. 2012;7:e34490.
16. Van Duyne R, Guendel I, Klase Z, Narayanan A, Coley W, Jaworski E, Roman J, Khan ZK, Lepene B, Kashanchi F. Localization and sub-cellular shuttling of HTLV-1 Tax with the miRNA machinery. PLoS One. 2012;7:e40662.
17. Padilha MDM, Santos NS, Silva TS, Braga SL, Medeiros GC, Lima TB, Barbosa EF, Ferreira FB. Perfil de citocinas na patogênese da infecção do vírus Linfotrópico de células T humanas HTLV-1. Braz J Health Rev. 2022;5(4):12294–311.
18. Padilha MDM, Silva TS, Braga SL, Santos NS, Lima TB, Medeiros GC, Barbosa EF, Ferreira FB. A expressão diferencial de microRNAs virais modula a patogenicidade da infecção. Rev Eletr Acervo Cient. 2023;23(3):1–11.
19. Sampey GC, Van Duyne R, Currer R, Das R, Narayanan A, Jaworski E, Hu W, Cross S, Monaco MCL, Kashanchi F. Complex role of microRNAs in HTLV-1 infections. Front Genet. 2012;3:1–16.
20. Shoraka S, Vahabpour R, Keshavarz M, Ataei-Pirkooh A, Asgari F, Bozorgmehr M, Farhadi A, Keyvani H. The role of hepatitis B virus genome variations in HBV-related HCC: effects on host signaling pathways. Front Microbiol. 2023;14:1–15.
21. Thirion M, Ochiya T. Roles of microRNAs in the Hepatitis B Virus Infection and Related Diseases. Viruses. 2013;5:2690–703.
22. Wang Y, Toh HC, Chow P, Chung AY, Meyers DJ, Cole PA, Ooi LL. Hepatitis B viral RNA directly mediates down-regulation of the tumor suppressor microRNA miR-15a/miR-16-1 in hepatocytes. J Biol Chem. 2013;288:18484–93.
23. Jiang R, Tang J, Chen Y, Deng L, Ji J, Xie Y, Sun B. miR-22 promotes HBV-related hepatocellular carcinoma development in males. Clin Cancer Res. 2011;17:5593–603.
24. Zhao Q, Fan YC, Wang K, Zhang JJ, Dong Q, Wu X, Li Y, Gao C. The miR-545/374a cluster encoded in the Ftx lncRNA is overexpressed in HBV-related hepatocellular carcinoma and promotes tumorigenesis and tumor progression. PLoS One. 2014;9:e109782.
25. Elghoroury EA, El-Ghany AA, Hassan EM, Ashmawy AM, El-Baz HA, Kassem NM. Detection of exosomal miR-18a and miR-222 levels in Egyptian patients with hepatic cirrhosis and hepatocellular carcinoma. Int J Immunopathol Pharmacol. 2022;36:1–13.
26. Bandopadhyay M, Bharadwaj M. Exosomal miRNAs in hepatitis B virus related liver disease: a new hope for biomarker. Gut Pathog. 2020;12:1–16.
27. Weidle UH, Birzele F, Kollmorgen G, Rüger R. MicroRNAs involved in metastasis of hepatocellular carcinoma: target candidates, functionality and efficacy in animal models and prognostic relevance. Cancer Genomics Proteomics. 2020;17:1–21.
28. Xie KL, Zhang YG, Liu J, Zeng Y, Wu H. MicroRNAs associated with HBV infection and HBV-related HCC. Theranostics. 2014;4:1176–92.
29. Shah N, Sukla S, Shah R, Kumar D, Nain CK, Rawat A. MicroRNAs in liver disease: bench to bedside. J Clin Exp Hepatol. 2013;3:231–42.
30. Braconi C, Kogure T, Valeri N, Huang N, Nuovo G, Costinean S, Croce CM, Patel T. microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. Oncogene. 2011;30:4750–6.
31. Szabo G, Bala S. MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol. 2013;10:542–52.
32. Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B, Mazzaferro V, Lowe SW, Croce CM, Dejean A. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A. 2009;107:264–9.
33. Jiang L, Qian L, Zheng J, Liu Y, Ding F, Zhang L, Wang Y, Liu J, Wang Y, Wang Z. Circulating microRNAs as biomarkers in hepatocellular carcinoma screening. Medicine (Baltimore). 2015;94:e1773.
34. Xu X, Tao Y, Shan L, Chen R, Jiang H, Qian Z, Cai F, Ma L, Yu Y. The role of microRNAs in hepatocellular carcinoma. J Cancer. 2018;9:3557–69.
35. Joshi N, Chittenden M, Verma R, O’Donoghue M, Ralph A, Khoo C, Houghton M. The involvement of microRNAs in HCV and HIV infection. Ther Adv Vaccines Immunother. 2022;10:25151355221095452.
36. Li GY, Wang Y, Liu Y, Chen L, Yang Q, Xu EM, Xu T, Li W, Wang S, Xu Y. HCV induced reduction in miR-181a impairs CD4+ T cell responses via over-expression of DUSP6. Hepatology. 2015;61:1163–73.
37. Cho HJ, Kim SS, Nam JS, Kang HG, Kim JW, Lee JH, Park KS, Kim BW, Song DS, Kim W, Yoon SK. Exosomal microRNA‐4661‐5p–based serum panel as a potential diagnostic biomarker for early‐stage hepatocellular carcinoma. Cancer Med. 2020;9:5459–72.
38. Khatun M, Ray RB. Mechanisms underlying hepatitis C virus-associated hepatic fibrosis. Cells. 2019;8:1249.
39. Padilha MDM, Feitosa RNM. Desregulação de microRNAs em processos patológicos do câncer. RECIMA. 2022;3(12):1–12.
40. Guan Y, Liu Y, Wang X, Gao S, Lu B, Wang Y, Liu B, Shen J, Lu J. NF-κB-DICER-miRs axis regulates TNF-α expression in responses to endotoxin stress. Int J Biol Sci. 2015;11:1257–68.
41. Cui J, Placzek WJ. Post-transcriptional regulation of anti-apoptotic BCL2 family members. Int J Mol Sci. 2018;19:1–22.
42. Taghavipour M, Dargahi L, Mikaeili H, Javadifar N, Ghasemi F, Kazemi T. Apoptotic functions of microRNAs in pathogenesis, diagnosis, and treatment of endometriosis. Cell Biosci. 2020;10:1–9.
43. Floyd DH, Zhang Y, Dey BK, Yang Y, Raplham M, Baehner L, Siegall CB, Blau CA, Ditta A, Gatti RA, Huang EJ. Novel anti-apoptotic microRNAs 582-5p and 363 promote human glioblastoma stem cell survival via direct inhibition of caspase 3, caspase 9, and Bim. PLoS One. 2014;9:e96239.
44. Williams M, Sandhu R, Crowe D, Blum W, Bhat R. Tumour suppressor microRNAs contribute to drug resistance in malignant pleural mesothelioma by targeting anti-apoptotic pathways. Cancer Drug Resist. 2019;2:1193–206.
45. Mahboonia K, Hadizadeh M, Asadi M, Farzanehfar M, Emami Razavi A, Alizadeh J, Najafi M. MicroRNAs in hepatocellular carcinoma pathogenesis: insights into mechanisms and therapeutic opportunities. Int J Mol Sci. 2024;25:1–50.
46. Kiliç A, Rodriguez G, Sosa RA, Yu X, Aghdassi A, Gupta S, Sahin M, Ruckert F, Ungefroren H. A systems immunology approach identifies the collective impact of 5 miRs in Th2 inflammation. JCI Insight. 2018;3:e97307.
47. Virga F, Cavallini C, Ceccarelli S, Angelucci A, Melino G, Amelio I. MicroRNA-mediated metabolic shaping of the tumor microenvironment. Cancers (Basel). 2021;13:1–17.
48. El-Daly SM, Abba ML, Patil N, Allgayer H. miRs-134 and -370 function as tumor suppressors in colorectal cancer by independently suppressing EGFR and PI3K signalling. Sci Rep. 2016;6:1–11.
49. Yuan Y, Wang J, Huang S, Li W, Lin W, Wang C, Zhang Y, Yang Y, Li H, Ma Y. ANXA1 inhibits miRNA-196a in a negative feedback loop through NF-κB and c-Myc to reduce breast cancer proliferation. Oncotarget. 2016;7:27007–20.
50. Roncarati R, Lupini L, Ravazzolo L, Brognara E, Venturi G, Bassi C, Pastore M, Grazi GL, Croce CM, Negrini M. The importance of microRNAs in RAS oncogenic activation in human cancer. Front Oncol. 2019;9:1–9.
License
Copyright (c) 2026 RECIMA21 - Revista Científica Multidisciplinar - ISSN 2675-6218
This work is licensed under a Creative Commons Attribution 4.0 International License.
Os direitos autorais dos artigos/resenhas/TCCs publicados pertecem à revista RECIMA21, e seguem o padrão Creative Commons (CC BY 4.0), permitindo a cópia ou reprodução, desde que cite a fonte e respeite os direitos dos autores e contenham menção aos mesmos nos créditos. Toda e qualquer obra publicada na revista, seu conteúdo é de responsabilidade dos autores, cabendo a RECIMA21 apenas ser o veículo de divulgação, seguindo os padrões nacionais e internacionais de publicação.